Idera’s cancer drug, IMO-2125, reported success as a combination therapy during early-stage trials.
- GlobeNewswire•4 days agoIdera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium
ORLANDO, Fla., Feb. 24, 2017-- Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today ...
- Motley Fool•6 days ago
Why investors should keep their eyes on Akebia Therapeutics, BioMarin Pharmaceutical, and Idera Pharmaceuticals.
IDRA : Summary for Idera Pharmaceuticals, Inc. - Yahoo Finance
Idera Pharmaceuticals, Inc. (IDRA)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.88 x 2400|
|Ask||1.89 x 12100|
|Day's Range||1.68 - 1.95|
|52 Week Range||1.19 - 3.33|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.40|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|